Spruce Biosciences

Where science meets compassion to deliver targeted therapies for serious neurological disorders.

[Spruce Biosciences @Spruce_Bio]

In MPS IIIB, deficient NAGLU enzyme activity allows heparan sulfate to build up in cells throughout the body, including the brain. Investigational TA-ERT is designed to deliver the missing enzyme directly to the CNS; it is not approved by FDA. https://t.co/33N3jxiF93

[Spruce Biosciences @Spruce_Bio]

We're looking forward to participating in a fireside chat next week at the Craig-Hallum Virtual Biotech Catalyst Conference.

Access the webcast here: https://t.co/G15IodkWpQ

$SPRB

[Spruce Biosciences @Spruce_Bio]

Today’s #SpruceRoots spotlight is Meghan Bowler, PhD. Meghan helps turn complex clinical trial data into insights that support our planned BLA submission for TA-ERT in MPS IIIB and help bring us closer to making a meaningful difference for patients & families affected by MPS IIIB

[Spruce Biosciences @Spruce_Bio]

#MPSIIIB natural history data will be presented at the 55th Child Neurology Society Annual Meeting in Montréal.
Poster #235 | Oct 15 | 12:30–1:45 & 5:30–7:30 p.m. EDT
Details: https://t.co/h3qWNPA4nL
#Sanfilippo #RareDisease #CNS2026

[Spruce Biosciences @Spruce_Bio]

We were honored to welcome Dr. Paul Harmatz and an MPS IIIB caregiver to our recent All Hands. Hearing directly from the community keeps patients and families at the heart of our work. #RareDisease #MPSIIIB

[Spruce Biosciences @Spruce_Bio]

Our intern program this year welcomed Amelia Graves, Anisa Mody and Trenton Chan to the Spruce team for the summer.

We’re proud to celebrate their time at Spruce and help foster the next generation of biotech leaders.

[Spruce Biosciences @Spruce_Bio]

We were proud to sponsor #ADVANCE2026. VP, Clinical Development Jessica Cohen Pfeffer, MD, shared updates on our Phase 3 TrAnsform Study of investigational TA-ERT. We were honored to connect with the Sanfilippo community.

[Spruce Biosciences @Spruce_Bio]

Next week, our CEO Javier Szwarcberg will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York. Access the live webcast here: https://t.co/CxuyP18r8M

$SPRB

https://t.co/wptAmtfV5S

[Spruce Biosciences @Spruce_Bio]

Earlier this month, the Spruce team attended the @MPSSociety Family Conference to listen, learn, and connect with members of the MPS IIIB community. Thank you to the families,caregivers, and advocates who shared their experiences. #RareDisease #MPSIIIB $SPRB

[Spruce Biosciences @Spruce_Bio]

We’re proud to launch https://t.co/33N3jxi7jv, a resource for families and caregivers of children with MPS IIIB, with information about the planned expanded access program and TrAnsform confirmatory study of investigational TA-ERT.
$SPRB
https://t.co/PJuSwaG3Jn

[Spruce Biosciences @Spruce_Bio]

We announced today positive pre-BLA meetings with the FDA and confirmed its TA-ERT BLA submission remains on track for Q4 2026. Another important step forward in addressing the unmet needs of the MPS IIIB community.
$SPRB

https://t.co/v6kHxgigp9

[Spruce Biosciences @Spruce_Bio]

Our CMO Adrian Quartel, M.D., FFPM is featured in @statnews’ “Up and Down the Ladder”: https://t.co/PbvBHufb63

Adrian gave a glimpse into his science-driven leadership and thoughtful approach to drug development, as well as what keeps him grounded outside of work.

[Spruce Biosciences @Spruce_Bio]

We announced our Q2 2026 results today. Visit our News & Events page for updates on the TA-ERT program, including our progress towards our planned BLA submission and confirmatory study of TA-ERT for the treatment of MPS IIIB. Full release: https://t.co/iiZdAhGxko

$SPRB

[Spruce Biosciences @Spruce_Bio]

Partnership with the patient community is critical to advancing progress in rare disease. We are proud to work alongside @CureSanfilippo and @MPSSociety to help expand access to TA-ERT for children and families affected by MPS IIIB.
$SPRB
https://t.co/k20j8tUT7K

[Spruce Biosciences @Spruce_Bio]

Welcome Jessica Cohen Pfeffer, M.D., to Spruce as Vice President, Clinical Development. Her expertise in rare disease drug development and enzyme replacement therapies will be invaluable as we advance TA-ERT for Sanfilippo Syndrome Type B (MPS IIIB).
$SPRB
https://t.co/0VxZsmJL3t

[Spruce Biosciences @Spruce_Bio]

We're pleased to welcome Adrian Quartel, M.D., FFPM as Chief Medical Officer. With 25+ years of rare disease and enzyme replacement therapy launch experience, Adrian will help advance TA-ERT towards potential commercialization for MPS IIIB. https://t.co/WehVI4U14p $SPRB

[Spruce Biosciences @Spruce_Bio]

Our people are the driving force behind Spruce's mission. Last month, we gathered at Oracle Park for a San Francisco Giants game to celebrate the season, connect beyond work, and enjoy time together as a team driven by passion and purpose. $SPRB

[Spruce Biosciences @Spruce_Bio]

We were honored to host Terri Klein, President & CEO of the National MPS Society, this week. As one of the most dedicated advocacy leaders in the Sanfilippo and broader MPS community, Terri generously shared her time and hard-won perspective with us.
#Sanfilippo #MPS #MPSIIIB

[Spruce Biosciences @Spruce_Bio]

Spruce is heading to the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit in Boston. CEO Javier Szwarcberg, M.D., M.P.H., will participate in a fireside chat and be available for investor meetings. $SPRB #SanfilippoSyndrome #MPSIIIB

[Spruce Biosciences @Spruce_Bio]

Spruce Biosciences was added to the Russell 3000® Index as part of FTSE Russell's 2026 semiannual reconstitution.
$SPRB
https://t.co/YlZDaAShR0